Anton Giorgio Failla
Nessuna posizione attualmente
Profilo
Dr. Anton G.
Failla is a Director-Corporate Business Development at Chiesi Farmaceutici SpA.
Dr. Failla was previously employed as Chief Financial Officer by Sorin Group Italia SRL and VP-Business Development & Strategic Planning by Novartis Consumer Health.
He also served on the board at Phenomix Corp., Cornerstone Therapeutics, Inc., Sorin Biomedica CRM SRL, Biofin Holding International NV, ELA Medical SAS, Bellco SRL, and Sorin Biomedica SRL.
He received his MBA from the University of Bocconi and a doctorate degree from the Polytechnic Institute of Turin.
Precedenti posizioni note di Anton Giorgio Failla
Società | Posizione | Fine |
---|---|---|
CORNERSTONE THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 03/02/2014 |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Direttore/Membro del Consiglio | 28/10/2010 |
Sorin Biomedica CRM SRL | Direttore/Membro del Consiglio | 01/07/2008 |
Sorin Group Italia Srl
Sorin Group Italia Srl Medical SpecialtiesHealth Technology MicroPort CRM SRL engages in the production and distribution of medical devices. It specializes in the development of medical technologies for the treatment of cardiovascular diseases. The company is headquartered in Saluggia, Italy. | Direttore Finanziario/CFO | 01/01/2008 |
Bellco SRL
Bellco SRL Medical SpecialtiesHealth Technology Bellco SRL provides therapies and systems for the treatment of renal failure, multiple organ failure, sepsis and congestive heart failure. It offers haemodiafiltration therapies, dialysis machines equipment, haemodialysers, blood lines, catheters, concentrates, and sorbent cartridges; pathologies for acute patients; and altered haemodynamics, renal hypoperfusion, and low cardiac output therapeutic system for neonatal patients. The company was founded in 1972 and is headquartered in Mirandola, Italy.^ | Direttore/Membro del Consiglio | 01/01/2007 |
Formazione di Anton Giorgio Failla
University of Bocconi | Masters Business Admin |
Politecnico di Torino | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 10 |
---|---|
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Bellco SRL
Bellco SRL Medical SpecialtiesHealth Technology Bellco SRL provides therapies and systems for the treatment of renal failure, multiple organ failure, sepsis and congestive heart failure. It offers haemodiafiltration therapies, dialysis machines equipment, haemodialysers, blood lines, catheters, concentrates, and sorbent cartridges; pathologies for acute patients; and altered haemodynamics, renal hypoperfusion, and low cardiac output therapeutic system for neonatal patients. The company was founded in 1972 and is headquartered in Mirandola, Italy.^ | Health Technology |
CHIESI Farmaceutici SpA
CHIESI Farmaceutici SpA Pharmaceuticals: MajorHealth Technology Chiesi Farmaceutici SpA develops and markets pharmaceutical products. The firm specializes in research, development and production of drugs in respiratory dosage forms, such as metered-dose inhalers and sterile unit dose vials. The company was founded by Giacomo Chiesi in 1935 and is headquartered in Parma, Italy. | Health Technology |
Sorin CRM SAS
Sorin CRM SAS Medical SpecialtiesHealth Technology Sorin CRM SAS designs and manufactures implantable pacemakers and defibrillators. It offers ICDs, leads, holter equipment, and electrophysiology catheters. The company was founded on July 25, 1977 and is headquartered in Clamart, France. | Health Technology |
Biofin Holding International NV
Biofin Holding International NV Medical DistributorsDistribution Services Part of LivaNova Plc, Biofin Holding International NV is an Italian company that distributes medical devices. The company is based in Milan, Italy. | Distribution Services |
Cornerstone Therapeutics, Inc.
Cornerstone Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cornerstone Therapeutics, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings. It acquires, develops and commercializes prescription pharmaceutical drugs. The company was founded on October 31, 2008 and is headquartered in Cary, NC. | Health Technology |
Sorin Biomedica SRL
Sorin Biomedica SRL Medical SpecialtiesHealth Technology Sorin Biomedica SRL manufactures medical electro medical systems and equipment. The company is headquartered in Saluggia, Italy. | Health Technology |
Sorin Biomedica CRM SRL | |
Novartis Consumer Health
Novartis Consumer Health Medical/Nursing ServicesHealth Services Novartis Consumer Health engages in the provision of healthcare services. The company is headquartered in Swaziland. | Health Services |
Sorin Group Italia Srl
Sorin Group Italia Srl Medical SpecialtiesHealth Technology MicroPort CRM SRL engages in the production and distribution of medical devices. It specializes in the development of medical technologies for the treatment of cardiovascular diseases. The company is headquartered in Saluggia, Italy. | Health Technology |
- Borsa valori
- Insiders
- Anton Giorgio Failla